Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada.
J Pharm Pharm Sci. 2012;15(4):499-509. doi: 10.18433/j3pk69.
Delirium is a common manifestation of acute, reversible, brain dysfunction in critically ill patients. It is associated with increased morbidity and mortality in the intensive care unit (ICU). Detection and prevention of risk factors for delirium is critical. Daily assessment for delirium should be part of the treatment strategies. Although, non-pharmacologic treatment have been successful, often, pharmacologic intervention is necessary. Currently, there are no approved medications indicated for the treatment of ICU delirium. The objective of this review article is to provide a comprehensive overview of non-pharmacologic and pharmacologic options for the treatment of ICU delirium. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.
谵妄是危重症患者急性、可逆性脑功能障碍的常见表现。它与重症监护病房（ICU）的发病率和死亡率增加有关。检测和预防谵妄的危险因素至关重要。每日评估谵妄应成为治疗策略的一部分。虽然非药物治疗已取得成功，但通常需要药物干预。目前，尚无批准的药物用于治疗 ICU 谵妄。本文的目的是全面概述 ICU 谵妄的非药物和药物治疗选择。本文接受 POST-PUBLICATION REVIEW。注册读者（见“读者须知”）可点击问题内容页面上的 ABSTRACT 进行评论。
